Results 121 to 130 of about 37,488 (288)

Apolipoproteins B and A1 in Ischemic Stroke Subtypes. [PDF]

J Stroke Cerebrovasc Dis, 2020
Kalani R, Krishnamoorthy S, Deepa D, Gopala S, Prabhakaran D, Tirschwell D, Sylaja PN.   +6 more
europepmc   +1 more source

Amyloid‐Related Imaging Abnormality (ARIA) Beyond the APOE‐ε4 Allele

Chronic Diseases and Translational Medicine, EarlyView.
Mechanism of action of monoclonal antibodies targeting Aβ in the treatment of AD. (A) Targets of various mAbs. (B) Mechanism of monoclonal antibody‐mediated clearance of Aβ. mAbs facilitate the clearance of Aβ by enhancing microglial‐mediated phagocytosis through the upregulation of TREM2 expression.
Valentinus Besin, Farizky Martriano Humardani, Fenny Lanawati Yudiarto, Paulus Anam Ong, Sulistyo Emantoko Dwi Putra, Ratih Asmana Ningrum   +5 more
wiley   +1 more source

Factores de riesgo cardiovascular y perfil apolipoprotéico en un grupo de adultos atendidos en un centro público de salud del estado Carabobo, Venezuela Cardiovascular risk factors and apolipoproteic profile in a group of adults treated in a public health center in Carabobo state, Venezuela

Revista Peruana de Medicina Experimental y Salud Pública, 2011
Objetivos. Comparar los niveles séricos de las apolipoproteínas A-I y B así como las relaciones Apo B/Apo A-I y HDL colesterol/Apo A-I según edad, sexo y factores de riesgo cardiovascular en individuos atendidos en un centro público de salud venezolano ...
Nelina Ruiz, Valerie Castillo, Francys Colina, Milagros Espinoza, Ulises Leal, Julio César Gonzalez   +5 more
doaj  

Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Alzheimer's disease (AD), characterized by β‐amyloid (Aβ) plaques and neurofibrillary tangles, is the leading cause of dementia globally. Donanemab is a humanized immunoglobulin G1 in development as a treatment to slow AD progression. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PKs), and immunogenicity of donanemab
Junyu Xu, Nan Zhao, Yihui Wang, Ivelina Gueorguieva, Chenxi Qian, Yimin Cui   +5 more
wiley   +1 more source

Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics

Proteins: Structure, Function, and Bioinformatics, EarlyView., 2023
Abstract Before the controversial approval of humanized monoclonal antibody lecanemab, which binds to the soluble amyloid‐β protofibrils, all the treatments available earlier, for Alzheimer's disease (AD) were symptomatic. The researchers are still struggling to find a breakthrough in AD therapeutic medicine, which is partially attributable to lack in ...
Sharif Arar, Md Anzarul Haque, Rakez Kayed   +2 more
wiley   +1 more source

Incorporation of a stable isotopically labeled amino acid into multiple human apolipoproteins.

Journal of Lipid Research, 1991
Procedures are presented for the separation and determination of the isotopic enrichment of multiple human apolipoproteins labeled in vivo with a stable isotope amino acid.
BW Patterson, DL Hachey, GL Cook, JM Amann, PD Klein   +4 more
doaj  

Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics

Clinical Pharmacology &Therapeutics, EarlyView.
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou, Rohit Rao, Monica E. Shapiro, Nessy Tania, Cody Herron, Cynthia J. Musante, Jim H. Hughes   +6 more
wiley   +1 more source

A quantitative analysis of apolipoprotein binding to SR-BI: multiple binding sites for lipid-free and lipid-associated apolipoproteins

Journal of Lipid Research, 2003
Competitive binding experiments were performed using Y1-BS1 adrenal cells to provide information about the interaction of HDL apolipoproteins with scavenger receptor class B, type I (SR-BI).
Stephen T. Thuahnai, Sissel Lund-Katz, G.M. Anantharamaiah, David L. Williams, Michael C. Phillips   +4 more
doaj  

Role of selenium in the pathophysiology of cardiorenal anaemia syndrome

ESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai, Minoru Yasukawa, Shigeru Shibata   +2 more
wiley   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source